Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation?
The clinical success of solid organ transplantation is still limited by the insufficiency of immunosuppressive regimens to control chronic rejection and late graft loss. Moreover, serious side effects caused by chronic immunosuppressive treatment increase morbidity and mortality in transplant patien...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/2/1752 |
| _version_ | 1797440990801297408 |
|---|---|
| author | Nina Pilat Romy Steiner Jonathan Sprent |
| author_facet | Nina Pilat Romy Steiner Jonathan Sprent |
| author_sort | Nina Pilat |
| collection | DOAJ |
| description | The clinical success of solid organ transplantation is still limited by the insufficiency of immunosuppressive regimens to control chronic rejection and late graft loss. Moreover, serious side effects caused by chronic immunosuppressive treatment increase morbidity and mortality in transplant patients. Regulatory T cells (Tregs) have proven to be efficient in the induction of allograft tolerance and prolongation of graft survival in numerous preclinical models, and treatment has now moved to the clinics. The results of the first Treg-based clinical trials seem promising, proving the feasibility and safety of Treg therapy in clinical organ transplantation. However, many questions regarding Treg phenotype, optimum dosage, antigen-specificity, adjunct immunosuppressants and efficacy remain open. This review summarizes the results of the first Treg-based clinical trials for tolerance induction in solid organ transplantation and recapitulates what we have learnt so far and which questions need to be resolved before Treg therapy can become part of daily clinical practice. In addition, we discuss new strategies being developed for induction of donor-specific tolerance in solid organ transplantation with the clinical aims of prolonged graft survival and minimization of immunosuppression. |
| first_indexed | 2024-03-09T12:16:26Z |
| format | Article |
| id | doaj.art-06f85a1b894a46b9925e01db0993d0f6 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T12:16:26Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-06f85a1b894a46b9925e01db0993d0f62023-11-30T22:45:07ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-01-01242175210.3390/ijms24021752Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation?Nina Pilat0Romy Steiner1Jonathan Sprent2Department of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, AustriaImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, AustraliaThe clinical success of solid organ transplantation is still limited by the insufficiency of immunosuppressive regimens to control chronic rejection and late graft loss. Moreover, serious side effects caused by chronic immunosuppressive treatment increase morbidity and mortality in transplant patients. Regulatory T cells (Tregs) have proven to be efficient in the induction of allograft tolerance and prolongation of graft survival in numerous preclinical models, and treatment has now moved to the clinics. The results of the first Treg-based clinical trials seem promising, proving the feasibility and safety of Treg therapy in clinical organ transplantation. However, many questions regarding Treg phenotype, optimum dosage, antigen-specificity, adjunct immunosuppressants and efficacy remain open. This review summarizes the results of the first Treg-based clinical trials for tolerance induction in solid organ transplantation and recapitulates what we have learnt so far and which questions need to be resolved before Treg therapy can become part of daily clinical practice. In addition, we discuss new strategies being developed for induction of donor-specific tolerance in solid organ transplantation with the clinical aims of prolonged graft survival and minimization of immunosuppression.https://www.mdpi.com/1422-0067/24/2/1752transplantationregulatory T cellstolerance |
| spellingShingle | Nina Pilat Romy Steiner Jonathan Sprent Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation? International Journal of Molecular Sciences transplantation regulatory T cells tolerance |
| title | Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation? |
| title_full | Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation? |
| title_fullStr | Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation? |
| title_full_unstemmed | Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation? |
| title_short | Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation? |
| title_sort | treg therapy for the induction of immune tolerance in transplantation not lost in translation |
| topic | transplantation regulatory T cells tolerance |
| url | https://www.mdpi.com/1422-0067/24/2/1752 |
| work_keys_str_mv | AT ninapilat tregtherapyfortheinductionofimmunetoleranceintransplantationnotlostintranslation AT romysteiner tregtherapyfortheinductionofimmunetoleranceintransplantationnotlostintranslation AT jonathansprent tregtherapyfortheinductionofimmunetoleranceintransplantationnotlostintranslation |